Pharmafile Logo

Impetus Digital official statement on COVID-19

At Impetus Digital, the health and wellbeing of our staff, clients, advisors, and their families is always our top priority. Recently, we have seen high numbers of advisors cancel their attendance for in-person meetings and ask to dial in remotely instead. This is a good thing, as evidence shows that social distancing will be key to flatten the curve and slow the spread of COVID-19.

We are big advocates for both public health and maintaining a viable economy. Therefore, we are strongly encouraging our clients to transfer their upcoming in-person meetings to virtual ones, either using synchronous web meetings, asynchronous touchpoints, or both. This is particularly relevant for large groups or if traveling is required, especially since many international travel restrictions are currently being enforced.

To do our part in keeping the population and economy healthy in these uncertain times, Impetus will waive cancellation fees for any new virtual consultancy, working group, medical education, or internal team meeting that is planned with us. This way, you can rest assured that if you need to quickly set up a virtual meeting in lieu of an in-person meeting, you will not be charged if you need to cancel it for whatever reason.

For more information on our different options for virtual meetings, please visit our website www.impetusdigital.com or make an appointment with Natalie Yeadon at www.meetwithnatalie.com to discuss your needs.

We are always respectfully here to serve our clients, especially during this time of tumult and uncertainty.

Stay safe and healthy,

The Impetus Team

This content was provided by Impetus Digital

Documents for download:

Company Details

 Latest Content from  Impetus Digital 

Top-5 Trends in Virtual KOL Engagement

Register now for one of our upcoming webinars (February 26-28)

Engaging with Different Perspectives – Top 10 Most Important Advisor Questions

In this quick clip, we highlight a vital tip from our 'Top 10 Most Important Advisor Questions' – essential for enhancing your virtual collaboration strategies in Pharma and Life Sciences....

Patient Advocate Engagement: A Customer Story

Learn how our client executed a series of 3 virtual touchpoints with 5 rare disease patient advocates to:- Develop a better understanding of the current treatment landscape and lived patient...

Tailored Marketing Strategies for Pharma – Top 10 Most Important Advisor Questions

In this video, we explore another crucial aspect of advisor questions when developing your virtual advisory board touchpoints – a key component for success in today's diverse healthcare landscape. 7....

Trends in Virtual Collaboration

Join us for a look at the top-5 emerging virtual collaboration trends...

Advisor Questions on Potential Data or Knowledge Gaps

As part of our top 10 most important advisor questions that every brand team should keep in mind when designing virtual advisory board touchpoints, here's another one to keep in...

On a journey to diverse, inclusive, and more efficient rare disease trials

Although orphan drugs represent a sizeable portion of new drug approvals, most rare diseases still lack effective treatment. Even more so than for other conditions, rare disease management contains large care...

Versatility! Top 10 benefits of virtual advisory boards

Here's another great tip on why the benefits of virtual advisory boards are superior to in-person and hybrid advisory boards. #10. Versatility! Another major advantage of using a virtual platform...

Clinical Trials Investigator and Patient Engagement Planning: A Customer Story

In the early lead-up to our client’s multi-center Rare Disease Phase 3 Clinical Trial, they first conducted an internal engagement planning Longitudinal Expert Engagement Plan™ (LEEP™) to conduct an informal...

New Playbook Alert: Virtual Patient Engagement

Authentic patient engagement and insight-gathering are becoming must-haves in Pharma. However, multiple obstacles remain before patient-centricity becomes more than a buzzword. In our latest playbook, we take a deep dive...